{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T13:06:54Z","timestamp":1717160814782},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T00:00:00Z","timestamp":1267747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00417-010-1333-x","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T04:56:36Z","timestamp":1267678596000},"page":"1057-1061","source":"Crossref","is-referenced-by-count":11,"title":["Genetic diversity and medicinal drug response in eye care"],"prefix":"10.1007","volume":"248","author":[{"given":"Barkur S.","family":"Shastry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,5]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 279:1200\u20131205","journal-title":"JAMA"},{"key":"1333_CR2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2796.2004.01326.x","volume":"255","author":"H Dormann","year":"2004","unstructured":"Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T, Levy M, Brune K, Hahan EG (2004) Readmissions and adverse drug reactions in internal medicine: the economic impact. J Int Med 255:653\u2013663","journal-title":"J Int Med"},{"key":"1333_CR3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10038-007-0200-z","volume":"52","author":"BS Shastry","year":"2007","unstructured":"Shastry BS (2007) SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet 52:871\u2013880","journal-title":"J Hum Genet"},{"key":"1333_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.tpj.6500338","volume":"6","author":"BS Shastry","year":"2006","unstructured":"Shastry BS (2006) Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6:16\u201321","journal-title":"Pharmacogenomics J"},{"key":"1333_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10038-005-0264-6","volume":"50","author":"BS Shastry","year":"2005","unstructured":"Shastry BS (2005) Genetic diversity and new therapeutic concepts. J Hum Genet 50:321\u2013328","journal-title":"J Hum Genet"},{"key":"1333_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ddr.10377","volume":"62","author":"BS Shastry","year":"2004","unstructured":"Shastry BS (2004) Role of SNP\/haplotype map in gene discovery and drug development: an overview. Drug Dev Res 62:142\u2013150","journal-title":"Drug Dev Res"},{"key":"1333_CR7","first-page":"379","volume":"11","author":"BS Shastry","year":"2003","unstructured":"Shastry BS (2003) SNPs and haplotypes: genetic markers for disease and drug response. Int J Mol Med 11:379\u2013382","journal-title":"Int J Mol Med"},{"key":"1333_CR8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.pharmtox.41.1.101","volume":"41","author":"HL McLeod","year":"2001","unstructured":"McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol 41:101\u2013121","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"1333_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s100380300004","volume":"48","author":"A Iida","year":"2003","unstructured":"Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2003) Catalog of 668 SNPs detected among 31 genes encoding potential drug targets on the cell surface. J Hum Genet 48:23\u201346","journal-title":"J Hum Genet"},{"key":"1333_CR10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ophtha.2008.04.020","volume":"115","author":"SE Moroi","year":"2008","unstructured":"Moroi SE, Jr H (2008) Progress toward personalized medicine for age-related macular degeneration. Ophthalmology 115:925\u2013926","journal-title":"Ophthalmology"},{"key":"1333_CR11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archopht.126.3.422","volume":"126","author":"JL Wiggs","year":"2008","unstructured":"Wiggs JL (2008) Genomic promise: personalized medicine for ophthalmology. Arch Ophthalmol 126:422\u2013423","journal-title":"Arch Ophthalmol"},{"key":"1333_CR12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1442-9071.2004.00833.x","volume":"32","author":"CA McCarty","year":"2004","unstructured":"McCarty CA (2004) The promise and challenges of personalized medicine for eye diseases. Clin Exp Ophthalmol 32:236\u2013237","journal-title":"Clin Exp Ophthalmol"},{"key":"1333_CR13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0896-1549(02)00051-2","volume":"15","author":"SG Schwartz","year":"2002","unstructured":"Schwartz SG, Mieler WF (2002) Medications and retinal toxicity. Ophthalmol Clin North Am 15:517\u2013528","journal-title":"Ophthalmol Clin North Am"},{"key":"1333_CR14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1442-9071.2009.02136.x","volume":"37","author":"PN Baird","year":"2009","unstructured":"Baird PN, Hageman GS, Franzco RHG (2009) New era for personalized medicine: the diagnosis and management of age-related macular degeneration. Clin Exp Ophthalmol 37:814\u2013821","journal-title":"Clin Exp Ophthalmol"},{"key":"1333_CR15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","volume":"308","author":"RJ Klein","year":"2005","unstructured":"Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308:385\u2013389","journal-title":"Science"},{"key":"1333_CR16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","volume":"308","author":"AO Edwards","year":"2005","unstructured":"Edwards AO, Ritter RIII, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308:421\u2013424","journal-title":"Science"},{"key":"1333_CR17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","volume":"308","author":"JL Haines","year":"2005","unstructured":"Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419\u2013421","journal-title":"Science"},{"key":"1333_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/431426","volume":"77","author":"S Zareparsi","year":"2005","unstructured":"Zareparsi S, Branham KE, LI M, Shah S, Klein RJ, Ott J, Hoh J, Abecasis GR, Swaroop A (2005) Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 77:149\u2013153","journal-title":"Am J Hum Genet"},{"key":"1333_CR19","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/hmg\/ddi353","volume":"14","author":"A Rivera","year":"2005","unstructured":"Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH (2005) Hypothetical LOC 387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14:3227\u20133236","journal-title":"Hum Mol Genet"},{"key":"1333_CR20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.1133807","volume":"314","author":"A Dewan","year":"2006","unstructured":"Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, Barnstable C, Pang CP, Hoh J (2006) HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314:982\u2013992","journal-title":"Science"},{"key":"1333_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000094617","volume":"220","author":"BS Shastry","year":"2006","unstructured":"Shastry BS (2006) Further support for the common variants in complement factor H (Y402H) and LOC 387715 (A69S) gene as major risk factors for the exudative age-related macular degeneration. Ophthalmologica 220:291\u2013295","journal-title":"Ophthalmologica"},{"key":"1333_CR22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s10038-007-0120-y","volume":"52","author":"BS Shastry","year":"2007","unstructured":"Shastry BS (2007) Assessment of the contribution of LOC 387715 gene polymorphism in a family with exudative age-related macular degeneration and heterozygous CFH variant (Y402H). J Hum Genet 52:384\u2013387","journal-title":"J Hum Genet"},{"key":"1333_CR23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/sj.eye.6702844","volume":"22","author":"N Patel","year":"2008","unstructured":"Patel N, Adewovin T, Chong NV (2008) Age-related macular degeneration: a perspective on genetic studies. Eye 22:768\u2013776","journal-title":"Eye"},{"key":"1333_CR24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"1333_CR25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR study group (2006) Ranibizumab verses verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"1333_CR26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA study group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"1333_CR27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp068185","volume":"355","author":"R Steinbrook","year":"2006","unstructured":"Steinbrook R (2006) The price of sight\u2014ranibizumab, bevacizumab and the treatment of macular degeneration. N Engl J Med 355:1409\u20131412","journal-title":"N Engl J Med"},{"key":"1333_CR28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/IAE.0b013e3181b32d13","volume":"29","author":"A Sheybani","year":"2009","unstructured":"Sheybani A, Kymes S, Schlief S, Apte R (2009) Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Retina 29:1404\u20131408","journal-title":"Retina"},{"key":"1333_CR29","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ophtha.2007.09.008","volume":"114","author":"MA Brantley Jr","year":"2007","unstructured":"Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (2007) Association of complement factor H and LOC 387715 genotype with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114:2168\u20132173","journal-title":"Ophthalmology"},{"key":"1333_CR30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bjo.2008.150995","volume":"93","author":"AY Lee","year":"2009","unstructured":"Lee AY, Rava AK, Kvmes SM, Shiels A, Brantley MA Jr (2009) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93:610\u2013613","journal-title":"Br J Ophthalmol"},{"key":"1333_CR31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","volume":"41","author":"SS Lynch","year":"2007","unstructured":"Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614\u2013625","journal-title":"Ann Pharmacother"},{"key":"1333_CR32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/FPC.0b013e3282f12a4e","volume":"17","author":"F Parmeggiani","year":"2007","unstructured":"Parmeggiani F, Costagliola C, Gemmati D, D\u2019Angelo S, Perri P, Scapoli GL, Catozzi L, Federici F, Sebastiani A, Incorvaia C (2007) Productive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet Genomics 17:1039\u20131046","journal-title":"Pharmacogenet Genomics"},{"key":"1333_CR33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/14622416.10.1.81","volume":"10","author":"F Parmeggiani","year":"2009","unstructured":"Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C (2009) Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 10:81\u201395","journal-title":"Pharmacogenomics"},{"key":"1333_CR34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1442-9071.2007.01534.x","volume":"35","author":"RK Koenekoop","year":"2007","unstructured":"Koenekoop RK, Lopez I, den Hollander AT, Allikmets R, Cremers FP (2007) Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Exp Ophthalmol 35:473\u2013485","journal-title":"Clin Exp Ophthalmol"},{"key":"1333_CR35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1573399810602040467","volume":"2","author":"M Maeda","year":"2006","unstructured":"Maeda M, Fujio Y, Azuma J (2006) MTHFR gene polymorphism and diabetic retinopathy. Curr Diabetes Rev 2:467\u2013476","journal-title":"Curr Diabetes Rev"},{"key":"1333_CR36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/112067210701700612","volume":"17","author":"SP Seitsonen","year":"2007","unstructured":"Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, Immonen IJ (2007) The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 17:943\u2013949","journal-title":"Eur J Ophthalmol"},{"key":"1333_CR37","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.ophtha.2009.03.011","volume":"116","author":"X Feng","year":"2009","unstructured":"Feng X, Xiao J, Longville B, Tan AX, Wu XN, Cooper MN, McAllister IL, Isaacs T, Palmer LJ, Constable IJ (2009) Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116:1908\u20131912","journal-title":"Ophthalmology"},{"key":"1333_CR38","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.178.6.3831","volume":"178","author":"M Laine","year":"2007","unstructured":"Laine M, Seitsonen JH, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hageman GS, Immonen I, Meri S (2007) Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 178:3831\u20133836","journal-title":"J Immunol"},{"key":"1333_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ophtha.2009.06.037","volume":"117","author":"I Immonen","year":"2010","unstructured":"Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER, Savolainen MJ, Liinamaa MJ (2010) Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 117:103\u2013108","journal-title":"Ophthalmology"},{"key":"1333_CR40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ophtha.2008.01.036","volume":"115","author":"ML Klein","year":"2008","unstructured":"Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW, Ott J, Seddon JM (2008) CFH and LOC 387715\/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115:1019\u20131025","journal-title":"Ophthalmology"},{"key":"1333_CR41","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinberg","year":"2004","unstructured":"Weinberg RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711\u20131720","journal-title":"Lancet"},{"key":"1333_CR42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archopht.1963.00960050447001","volume":"70","author":"WM Grant","year":"1963","unstructured":"Grant WM (1963) Glaucoma from topical corticosteroids. Arch Ophthalmol 70:445\u2013446","journal-title":"Arch Ophthalmol"},{"key":"1333_CR43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0002-9394(64)92500-0","volume":"57","author":"B Becker","year":"1964","unstructured":"Becker B, Hahn KA (1964) Topical corticoids and heredity in primary open\u2013angle glaucoma. Am J Ophthalmol 57:543\u2013551","journal-title":"Am J Ophthalmol"},{"key":"1333_CR44","first-page":"659","volume":"13","author":"V Szabo","year":"2007","unstructured":"Szabo V, Borgulya G, Filkorn T, Majnik J, Banyasz I, Nagy ZZ (2007) The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. Mol Vis 13:659\u2013666","journal-title":"Mol Vis"},{"key":"1333_CR45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13816810802320217","volume":"29","author":"SM Gerzenstein","year":"2008","unstructured":"Gerzenstein SM, Pletcher MT, Cervino AC, Tsinoremas NF, Young B, Puliafito CA, Fini ME, Schwartz SG (2008) Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide. Ophthalmic Genet 29:166\u2013170","journal-title":"Ophthalmic Genet"},{"key":"1333_CR46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/jop.2008.0028","volume":"25","author":"Y Yang","year":"2009","unstructured":"Yang Y, Wu K, Yuan H, Yu M (2009) Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 25:163\u2013171","journal-title":"J Ocul Pharmacol Ther"},{"key":"1333_CR47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-005-0052-4","volume":"61","author":"T Nieminen","year":"2005","unstructured":"Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimaki T, Kahonen M (2005) Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. Eur J Clin Pharmacol 61:811\u2013819","journal-title":"Eur J Clin Pharmacol"},{"key":"1333_CR48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archopht.126.7.959","volume":"126","author":"CA McCarty","year":"2008","unstructured":"McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA (2008) Intraocular pressure response to topical beta blockers associated with an ADRB2 single-nucleotide polymorphism. Arch Ophthalmol 126:959\u2013963","journal-title":"Arch Ophthalmol"},{"key":"1333_CR49","first-page":"811","volume":"11","author":"G Fuchsjager-Mayrl","year":"2005","unstructured":"Fuchsjager-Mayrl G, Markovic O, Losert D, Lucus T, Wachek V, Muller M, Schmutterer L (2005) Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis 11:811\u2013815","journal-title":"Mol Vis"},{"key":"1333_CR50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2007.03.025","volume":"114","author":"M Sakurai","year":"2007","unstructured":"Sakurai M, Higashide T, Takahashi M, Sugiyama K (2007) Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114:1039\u20131045","journal-title":"Ophthalmology"},{"key":"1333_CR51","first-page":"46","volume":"3","author":"IM MacDonald","year":"2009","unstructured":"MacDonald IM (2009) Pharmacogenetics\u2014getting closer. Open Ophthalmol J 3:46\u201354","journal-title":"Open Ophthalmol J"},{"key":"1333_CR52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.tpj.6500181","volume":"3","author":"NC McLaren","year":"2003","unstructured":"McLaren NC, Moroi SE (2003) Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 3:197\u2013201","journal-title":"Pharmacogenomics J"},{"key":"1333_CR53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14622416.5.5.571","volume":"5","author":"FW Frueh","year":"2004","unstructured":"Frueh FW, Gurwitz D (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5:571\u2013579","journal-title":"Pharmacogenomics"},{"key":"1333_CR54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1387-2656(08)00015-X","volume":"14","author":"TD Richmond","year":"2008","unstructured":"Richmond TD (2008) The current status and future potential of personalized diagnostics: streamlining a customized process. Biotechnol Ann Rev 14:411\u2013422","journal-title":"Biotechnol Ann Rev"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1333-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-010-1333-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1333-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:53Z","timestamp":1559058053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-010-1333-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,5]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s00417-010-1333-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,5]]}}}